Navigation Links
Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Association's 69th Scientific Sessions
Date:6/1/2009

gram expected to enroll approximately 7,800 patients and potentially represents a targeted treatment option for the millions of patients who need to better manage their weight. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about lorcaserin's potential to be the first in a new class of agonists or treatment option; lorcaserin's selectivity; enrollment in the lorcaserin Phase 3 program; lorcaserin's patent coverage; and Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectat
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
7. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
8. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
9. Critical Pharmaceuticals Enter Sustained Release hGH Arena
10. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
11. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014  TNI BioTech, Inc. (OTCQB: ... focused on the development, marketing and distribution of ... definitive proxy materials with the Securities and Exchange ... of Shareholders to be held on Thursday, September ... The record date for determining those shareholders eligible ...
(Date:7/28/2014)... TOKYO , July 28, 2014 /PRNewswire/ ... appointed Roger Crystal , MD as Vice President ... the Global Business Development Product Acquisition & Licensing team ... in developing business strategy and partnerships in the precision ... to partner with biotechnology and pharmaceutical companies across the ...
(Date:7/28/2014)... -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI ) ... 2014 financial results for the period ended June 30, 2014, ... will host a conference call and webcast that day at ... slide presentation relating to the call will be available via ... Call Details To access the live conference call via ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2
(Date:7/28/2014)... July 28, 2014 Ticket Down ... Roma tickets in Dallas, TX at the Cotton Bowl. ... in the USA and it is an eight team tourney. ... the world including teams from La Liga, Serie A, English ... will battle it out on the pitch include: Manchester ...
(Date:7/28/2014)... Ticket Down is a dependable source ... FL at the Sun Life Stadium in early September. ... and Brazil has is one that has continues to go ... forming on a consistent basis. The rivalry between South ... the recent 2014 World Cup. To the delight of ...
(Date:7/28/2014)... Steven Reinberg HealthDay Reporter ... dementia and heart rhythm irregularities are more likely to get ... In fact, the study of more than 16,000 people ... more likely to get a pacemaker than those without the ... is why folks with dementia are so much more likely ...
(Date:7/28/2014)... York, NY (PRWEB) July 28, 2014 ... literacy organization that has donated more than 200,000 books ... in 2001, announces the launch of Brooke’s Cooks, a ... values, while encouraging healthy living among at-risk children and ... Cooks will include a series of nutrition information workshops, ...
(Date:7/28/2014)... July 28, 2014 UT Southwestern Medical Center ... and irreversibly interferes with the activity of a ... tumors. , The molecule, SML-8-73-1 (SML), interferes with ... oncogene homolog. The gene produces proteins called K-Ras ... can result in normal cells dividing uncontrollably and ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for Sept. 5th Showdown 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 2Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 3Health News:Brooke Jackman Foundation Launches Brooke's Cooks, New Initiative to Promote Healthy Living Among At-Risk Youth and Their Families 4Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2
... Online Science Writers Webinar , NCI and ASCO will ... Wide Web that will explore key issues surrounding cancer ... experts from the United States, Africa, Asia and India ... Incidence, Survival and Mortality Trends , The State ...
... planning proton treatments makes it possible to precisely ... distributed inside the patient,s body, PALO ALTO, Calif., ... has received FDA 510(k) clearance for a new proton,scanning ... beams are used to target tumors and other abnormalities. ...
... Reliable, Quick Patient-Information Retrieval From Multiple ... Ill., Dec. 14 AT&T Inc. (NYSE: ... Associates, Ltd. (JOHA) has,awarded AT&T a three-year ... addition to other network solutions. Continuing its ...
... AMSTERDAM, December 14 Kiadis Pharma announced ... for regulatory,classification as a "cell based" medicinal product ... the European Medicines Agency (EMEA). Based upon,this regulatory ... a,next step Kiadis Pharma will file for orphan ...
... Online Help for Living Longer, ... Stronger, KIRKLAND, ... odds of needing long term care,increase. One solution is long term care insurance ... Financial Partners,(LTCFP), "is the insurance plus health habits to keep yourself on your ...
... generation begins to join the ranks of the retired so ... consumers, says a new study funded by the Economic and ... media creations, it seems that the caricatures of silver surfers ... of older people increasingly mirror those of the rest of ...
Cached Medicine News:Health News:NCI/ASCO host science writers' seminar 2Health News:Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance 2Health News:Eclipse(TM) Proton Scanning Algorithm from Varian Medical Systems Receives FDA Clearance 3Health News:Local Joliet Physician Group Selects AT&T for Managed Online Data Solutions 2Health News:Local Joliet Physician Group Selects AT&T for Managed Online Data Solutions 3Health News:ATIR Classified as "Cell Based" Medicinal Product by the EMEA 2Health News:As More Americans Live to 100, Long Term Care Insurance Leader Gives Health Assist 2Health News:Retirees spending freely 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: